News

Clinical Trial to Assess Effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid Begins in Australia

Australian regenerative medicine company Orthocell Limited today announced that it has recruited and treated its first patient in a randomised, controlled clinical trial of Ortho-ATI® versus corticosteroid injection, for the treatment of rotator cuff tendinopathy and tear in the shoulder.

Rotator cuff tendinopathy and tear (which manifests as severe shoulder pain) is a common and often difficult injury to treat and affects more than 50% of adults over 50 years of age. Rotator cuff injuries may lead to considerable disability, reduced quality of life, and absenteeism from work, and are a significant burden on healthcare resources. This burden is expected to increase as the population ages, and as a result, new treatments are required that address the underlying pathology of the injury, not just the symptoms.

The objective of this clinical trial is to assess the effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear. To be eligible for the trial, patients must have failed previous conservative treatment options, including previous injection treatment and physiotherapy. The trial will be led by Clinical Professor Allan Wang, President of the Australian Elbow and Shoulder Society, Clinical associate Professor Bill Breidahl and Professor …

To read more subscribe
Show More

Related Articles

Leave a Reply

Close